Preliminary results from phase II study of combination treatment with HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIb, IIIc, or IV unresectable or metastatic melanoma.
Robert Hans Ingemar Andtbacka(University of Utah), Kenneth F. Grossmann(University of Utah), Hung T. Khong(University of Utah), Adil Daud(Memorial Sloan Kettering Cancer Center), Matthew H. Taylor(Providence Portland Medical Center), Aislyn Boran(Icahn School of Medicine at Mount Sinai), John T. Vetto(Oregon Health & Science University), Richard S. Ungerleider(Theradex Oncology (United States)), Merrick I. Ross(The University of Texas MD Anderson Cancer Center), Sanjiv S. Agarwala(Goethe University Frankfurt), Maki Tanaka(Takara (Japan)), Rogerio I. Neves(Saint John's Health Center)
Cited by 19
Related Papers
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
|Nature Medicine|2018|1k
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia.
|Journal of Clinical Oncology|1996|914
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|1999|763